Howard Horn Sells 4,653 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 4,653 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $23.77, for a total transaction of $110,601.81. Following the completion of the sale, the chief financial officer owned 105,689 shares of the company’s stock, valued at $2,512,227.53. This trade represents a 4.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Howard Horn also recently made the following trade(s):

• On Friday, May 1st, Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $24.90, for a total transaction of $116,606.70.
• On Wednesday, April 1st, Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $20.97, for a total transaction of $98,202.51.
• On Tuesday, March 3rd, Howard Horn sold 1,635 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $22.40, for a total transaction of $36,624.00.

Ultragenyx Pharmaceutical Price Performance

RARE traded down $1.09 on Monday, hitting $22.85. The company had a trading volume of 2,327,481 shares, compared to its average volume of 1,556,020. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.29 and a 52-week high of $42.37. The stock has a fifty day simple moving average of $23.47 and a 200-day simple moving average of $25.71. The firm has a market capitalization of $2.25 billion, a P/E ratio of -3.74 and a beta of 0.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The company had revenue of $136.00 million during the quarter, compared to analysts’ expectations of $158.19 million. During the same quarter last year, the business earned ($1.57) earnings per share. The business’s quarterly revenue was down 2.2% on a year-over-year basis. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the company. Assetmark Inc. raised its holdings in Ultragenyx Pharmaceutical by 1,706.7% in the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the last quarter. Huntington National Bank raised its holdings in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares during the last quarter. Parallel Advisors LLC raised its holdings in Ultragenyx Pharmaceutical by 778.4% in the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,440 shares during the last quarter. Leonteq Securities AG raised its holdings in Ultragenyx Pharmaceutical by 288.5% in the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,333 shares during the last quarter. Finally, Danske Bank A S purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $39,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on RARE shares. The Goldman Sachs Group lowered shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $61.00 to $25.00 in a report on Tuesday, March 24th. Guggenheim decreased their target price on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Barclays decreased their target price on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. Wedbush decreased their target price on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Finally, Truist Financial raised shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.56.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.